Nirsevimab EMA regulatory submission accepted under accelerated assessment
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
It is being developed by Pune-based Gennova Biopharmaceuticals
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
Subscribe To Our Newsletter & Stay Updated